Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga viruses
This grant supports research to develop monoclonal antibodies against key emerging viruses, advancing candidates through preclinical and early clinical stages to boost EU pandemic preparedness.
Funder: European Commission
Due Dates: April 13, 2027: Full application submission deadline (single-stage topic)
Funding Amounts: €9,000,000–€10,000,000 per project | 4 grants expected | Project duration typically 3–5 years
Summary: Supports research to develop monoclonal antibodies for prevention and treatment of major emerging viral infections, advancing candidates toward clinical use and strengthening EU preparedness.
Key Information: Proposals must target one eligible virus; clinical study annex required; legal entities from China are not eligible.
Description
This Horizon Europe call funds collaborative research and development of monoclonal antibodies for the prevention and treatment of selected emerging or re-emerging viral infections, specifically targeting one of the following viruses: Ebola, Marburg, Crimean-Congo Hemorrhagic Fever, Rift Valley Fever, Enterovirus D68, or Chikungunya. Projects should advance existing monoclonal antibody candidates through in-vitro and in-vivo characterization, animal testing, evaluation of antibody-dependent enhancement (ADE) risk, GMP batch production, and first-in-human clinical safety studies. The aim is to diversify and accelerate the global portfolio for antiviral preparedness and reinforce the EU’s leadership in this field. Engagement with regulatory bodies, leveraging of state-of-the-art research infrastructures, and participation from start-ups and SMEs are strongly encouraged.
